[en] In this report, we present a novel histone deacetylase inhibitor (HDACi) (N-Hydroxy-6-(5-nitro-naphtalimide)-hexanamide: ES8) that
efficiently inhibits angiogenesis in relevant ex vivo models (Human umbilical vein endothelial cells (HUVEC), 3D aortic ring assay)
and in vivo (chick chorioallantoic membrane (CAM), Zebrafish).
Transcriptomic profiling reveals a set of ES8 specific genes that are not affected by the prototypical HDACi suberoylanilide hydroxamic
acid (SAHA). Finally, ES8 also reduced tumor growth in mouse models of small cell lung cancer. Availability of a novel compound not
centered exclusively on inhibition of angiogenic factors and inducing a characteristic transcription profile may be of interest to overcome resistance to currently used chemotherapies.
Sixth Research Framework Programme of the European Union (project INCA LSHC-CT-2005-018704) BELVIR Inter university Attraction Poles Program 7/45 initiated by the Belgian Science Policy Office Action de Recherche Concertée "Glyvir” of the Communauté française de Belgique The “Neoangio” excellence program Agricultureislife Synbiofor The “Plan Cancer” of the Service Public Fédéral
Funders :
F.R.S.-FNRS - Fonds de la Recherche Scientifique Télévie Belgian Foundation Against Cancer SPW DGO6 - Service Public de Wallonie. Economie, Emploi, Recherche CFB - Communauté française de Belgique CAC - Centre anticancéreux près l'Université de Liège asbl ULiège. GxABT - Liège Université. Gembloux Agro-Bio Tech ULg FSR - Université de Liège. Fonds spéciaux pour la recherche BELSPO - Belgian Science Policy Office
Funding text :
The “Partenariat Public Privé” PPP INCA of the “Direction générale des Technologies, de la Recherche et de l’Energie/DG06” of the Walloon government
